Non-Small Cell Lung Cancer Clinical Trial 20203080

[LCID Study Number: 20203080]

EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

The purpose of this study is to evaluate treatment with antibody (durvalumab) plus chemotherapy and radiation therapy (chemoradiation) in patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable).

Disease/Condition: Non-Small Cell Lung Cancer

Department: Hematology and Oncology

Location: Beverly Hospital; Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-756-5095

View NCT ID 04092283 on ClinicalTrials.gov
Protocol #: 20203080
Principal Investigator(s): Krishna S. Gunturu
Study Coordinator(s): Carol Bovest
Trial Phase: Sponsor Initiated Study Phase 3